Caricamento...
Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds
Introduction. Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results. However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today. Aim. To assess the cost of treatment with NXB...
Salvato in:
| Pubblicato in: | Biomed Res Int |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Hindawi Publishing Corporation
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5331316/ https://ncbi.nlm.nih.gov/pubmed/28293640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/9567498 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|